Biocon: Biocon Biologics, a subsidiary of Biocon, reported encouraging findings from Phase III clinical trials for its ...

Piramal Pharma has set an ambitious target to double its revenue to $2 billion by FY30, while also tripling its Ebitda, ...

Under the terms of this agreement, Biocon will develop and manufacture the products, and Tabuk Pharmaceuticals will hold the ...

The global psoriatic arthritis (PsA) treatment market is poised for remarkable expansion, with an anticipated valuation of ...

Piramal Pharma aims to double its revenue to $2 billion by FY30, while tripling its Ebitda, said company Chairperson Nandini ...